特应性皮炎；Janus激酶抑制剂；度普利尤单抗；乌帕替尼；托法替布," /> 特应性皮炎；Janus激酶抑制剂；度普利尤单抗；乌帕替尼；托法替布,"/> atopic dermatitis,Janus kinase (JAK) inhibitors,dupilumab,upadacitinib,tofacitinib,"/> Janus激酶抑制剂治疗儿童难治性特应性皮炎二例

中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (3): 190-192.doi: 10.12144/zgmfskin202403190

• 临床研究 • 上一篇    下一篇

Janus激酶抑制剂治疗儿童难治性特应性皮炎二例

韩京宏1,2,刘红1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2024-03-15 发布日期:2024-02-27

Two children with refractory atopic dermatitis successfully treated with Janus kinase inhibitors

HAN Jinghong1,2, LIU Hong1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China;2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2024-03-15 Published:2024-02-27

PDF (PC)

87

摘要： 特应性皮炎是一种常见的慢性炎症性皮肤病，严重影响患者的生活质量。近几年，多种新型生物制剂和小分子口服药物已被批准用于治疗特应性皮炎。Janus激酶抑制剂通过抑制多种Th2细胞介导的炎症、表皮屏障功能受损、瘙痒信号传导等途径，对特应性皮炎起到治疗作用。本文报道了两例难治性特应性皮炎儿童患者成功使用JAK抑制剂治疗的案例。

关键词: 特应性皮炎；Janus激酶抑制剂；度普利尤单抗；乌帕替尼；托法替布')">">特应性皮炎；Janus激酶抑制剂；度普利尤单抗；乌帕替尼；托法替布

Abstract: Atopic dermatitis (AD) is a common chronic inflammatory skin disease that significantly impairs the quality of life. Recently, novel biologics and small-molecule oral drugs have gained approval for the treatment of AD. Janus kinase (JAK) inhibitors play a therapeutic role in atopic dermatitis by inhibiting various Th2 cell-mediated inflammation, impaired epidermal barrier function, and pruritus signaling pathways. This article reports two cases of pediatric patients with refractory atopic dermatitis successfully treated with JAK inhibitors.

Key words: atopic dermatitis')">atopic dermatitis, Janus kinase (JAK) inhibitors, dupilumab, upadacitinib, tofacitinib